Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kiora Pharmaceuticals Inc (KPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: KPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -21.25% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.19M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 893076 | Beta -0.68 | 52 Weeks Range 2.51 - 4.86 | Updated Date 06/19/2025 |
52 Weeks Range 2.51 - 4.86 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -48421.22% |
Management Effectiveness
Return on Assets (TTM) -15.83% | Return on Equity (TTM) -41.13% |
Valuation
Trailing PE - | Forward PE 2.41 | Enterprise Value -14754379 | Price to Sales(TTM) 459.62 |
Enterprise Value -14754379 | Price to Sales(TTM) 459.62 | ||
Enterprise Value to Revenue 569.41 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 3043860 | Shares Floating 2074267 |
Shares Outstanding 3043860 | Shares Floating 2074267 | ||
Percent Insiders 3.6 | Percent Institutions 45.65 |
Analyst Ratings
Rating 4 | Target Price 11 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kiora Pharmaceuticals Inc
Company Overview
History and Background
Kiora Pharmaceuticals Inc. (formerly EyeGate Pharmaceuticals) is a biopharmaceutical company focused on developing and commercializing products for the treatment of ophthalmic diseases. Founded as EyeGate Pharmaceuticals, it later rebranded as Kiora Pharmaceuticals to reflect its broader focus. The company has evolved through various clinical trials and strategic shifts in its pipeline.
Core Business Areas
- Retinal Diseases: Developing therapies for degenerative eye diseases, including inherited and age-related conditions, such as retinitis pigmentosa.
Leadership and Structure
The company's leadership team consists of the CEO, CFO, and other key executives. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- KIO-301: A light-sensitive small molecule designed to restore vision in patients with advanced retinitis pigmentosa. Itu2019s currently in clinical development. Competitors include companies developing gene therapies and other treatments for inherited retinal diseases, although KIO-301 utilizes a different mechanism of action by converting residual non-functional retinal cells into functional ones.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is driven by the increasing prevalence of eye diseases, aging populations, and technological advancements in treatment options. The market is competitive, with companies developing innovative therapies for a range of conditions.
Positioning
Kiora is positioning itself as a leader in developing novel therapies for underserved ophthalmic conditions, particularly focusing on retinitis pigmentosa. Its competitive advantage lies in its unique light-sensitive small molecule approach.
Total Addressable Market (TAM)
The TAM for retinitis pigmentosa and other retinal diseases is significant, estimated to be in the billions of dollars. Kiora is targeting a portion of this market with its KIO-301 program.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (KIO-301)
- Focus on underserved ophthalmic conditions
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Early-stage development pipeline
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other ophthalmic indications
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AGN
- LLY
- VRTX
Competitive Landscape
Kiora faces competition from larger pharmaceutical companies with established ophthalmic portfolios. Its advantage lies in its unique approach, but its limited resources are a disadvantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by clinical trial advancements and securing funding.
Future Projections: Future growth is dependent on the successful development and commercialization of KIO-301.
Recent Initiatives: Recent initiatives include advancing KIO-301 through clinical trials and exploring potential partnerships.
Summary
Kiora Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focusing on innovative treatments for retinal diseases. Its success hinges on the clinical trial outcomes of KIO-301 and its ability to secure funding. The company needs to navigate regulatory hurdles and competition from larger players while capitalizing on potential partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The analysis is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiora Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Encinitas, CA, United States | ||
IPO Launch date 2015-07-31 | President, CEO & Director Dr. Brian M. Strem Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.kiorapharma.com |
Full time employees 12 | Website https://www.kiorapharma.com | ||
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.